Zyversa Therapeutics Inc (ZVSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,591 | -2,827 | -98,298 | -84,960 | -82,057 |
| Depreciation Amortization | 5 | 3 | 11,905 | 11,903 | 11,900 |
| Income taxes - deferred | 10 | N/A | -9,479 | -8,883 | -8,883 |
| Accounts payable and accrued liabilities | -115 | -304 | 2,406 | 2,872 | 2,118 |
| Other Working Capital | -586 | -1,263 | 2,600 | 4,001 | 2,302 |
| Other Operating Activity | 586 | 614 | 82,145 | 69,134 | 69,621 |
| Operating Cash Flow | $-5,691 | $-3,777 | $-8,721 | $-5,934 | $-4,997 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,673 | 2,673 | 19,082 | 14,082 | 11,016 |
| Common Stock Repurchased | N/A | N/A | -7 | -7 | -7 |
| Other Financing Activity | 0 | 0 | -13,118 | -12,465 | -11,685 |
| Financing Cash Flow | $2,673 | $2,673 | $5,956 | $1,610 | $-676 |
| Beginning Cash Position | 3,138 | 3,138 | 5,902 | 5,902 | 5,902 |
| End Cash Position | 120 | 2,034 | 3,138 | 1,579 | 229 |
| Net Cash Flow | $-3,018 | $-1,104 | $-2,765 | $-4,324 | $-5,674 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,691 | -3,777 | -8,721 | -5,934 | -4,997 |
| Free Cash Flow | -5,691 | -3,777 | -8,721 | -5,934 | -4,997 |